Sirolimus |
mTor inhibitor: leads to inhibition of T lymphocyte activation and proliferation; inhibition of antibody production |
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE). Age ≥ 18 years Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old |
NCT04341675 NCT04371640
|
|
|
Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old |
NCT04371640 |
Hydroxychloroquine, Azithromycin, Sirolimus |
Senolytic drug: Hydroxychloroquine alkalinizes the pH in lysosomes, which accumulate in large numbers in senescent cells |
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients (COVID19-HOPE). Age ≥ 18 years |
NCT04374903 |
Quercetin |
Anti-inflammatory agent |
Effect of Quercetin on Prophylaxis and Treatment of COVID-19. Age ≥ 18 years |
NCT04377789 |
Hydrocortisone |
Senolytic drug: SASP inhibition |
Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID). Age ≥ 18 years |
NCT04348305 |
Ruxolitinib |
Senolytic drug: inhibition of the signalling of cytokines and growth factor receptors that use JAK1 and JAK2 for signalling |
Safety and Efficacy of Ruxolitinib for COVID-19. 18–89 years |
NCT04348071 |
|
|
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil). Age ≥ 18 years |
NCT04359290 |
|
|
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection. 12 years and older |
NCT04355793 |
|
|
Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam). Age ≥ 18 years |
NCT04338958 |
Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or Tocilizumab |
Combination of senolytic drugs; antiviral; and immunomodulation |
Randomized Evaluation of COVID-19 Therapy (RECOVERY). All ages |
NCT04381936 |